Stryker Shares Rise 0.81% on Robotic Surgery Push, Hits 220th in U.S. Trading Volume

Stryker Corporation (SYK) closed 0.81% higher on October 7, 2025, with a trading volume of $510 million, ranking 220th among U.S. stocks. The medical technology leader's performance was driven by strategic developments in its surgical and orthopedic divisions, including progress on key regulatory approvals for next-generation robotic systems. Recent announcements highlighted expanded partnerships with hospital networks in the Midwest and Southeast, signaling growing adoption of its Mako robotic-assisted surgery platform.

Analysts noted increased investor confidence following a management update on supply chain optimizations, which reduced production delays for trauma and spine products. The company also confirmed continued demand for its bone cement systems despite competitive pressures in the orthopedic market. Institutional investors showed heightened interest, with several large orders recorded during afternoon trading sessions.

To ensure accurate modeling of the proposed strategy, please confirm the following parameters: 1) Should the universe be limited to U.S.-listed common stocks on NYSE and NASDAQ, or does a different market scope apply? 2) For portfolio execution, will positions be established at daily closing prices (or next-day open) and liquidated at the following close? 3) Are there specific transaction cost assumptions (e.g., commission rates, slippage estimates) to be applied? 4) Regarding the back-test platform, is the proposed approach of constructing an equal-weight synthetic index for the top 500 volume stocks acceptable, or would you prefer an alternative methodology such as using representative ETFs?